Epsilico - About the company
Epsilico is a seed company based in Berlin (Germany), founded in 2020 by Cuong To and Christian Wirsching. It operates as a Generative AI technology for designing biologics. Epsilico has raised an undisclosed amount in funding. The company has 419 active competitors, including 150 funded and 98 that have exited. Its top competitors include companies like BioMarin Pharmaceutical, Ultragenyx and Upstream Bio.
Company Details
Generative AI technology for designing biologics. The platform leverages generative AI to create biopharmaceuticals for hard-to-drug targets such as GPCRs, secreted proteins, ion-channels, and transporter proteins. It combines hypothesis-driven engineering, an AI protein design pipeline, and laboratory automation to design the 3D structure of therapeutic proteins that can bind to selected drug targets. Its geometrical deep learning models are used to tailor the shapes of the proteins to suit distinct drug-target families and for optimal performance in therapeutic applications.
- Website
- www.epsilico.com/
- Email ID
- *****@epsilico.com
- Phone Number
- +49 **********
Key Metrics
Founded Year
2020
Location
Berlin, Germany
Stage
Seed
Latest Funding Round
Investors
Ranked
177th among 419 active competitors
Similar Companies
Legal entities associated with Epsilico
Epsilico is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Cinference GmbH CIN: HRB223875 , Germany, Active | Dec 03, 2020 | - | - |
Sign up to download Epsilico's company profile
Epsilico's funding and investors
Epsilico has raised funding over 2 rounds. Its first funding round was on Oct 01, 2022. Its latest funding round was a Seed round on 2023 for $*****. 1 investor participated in its latest round. Epsilico has 3 institutional investors.
Here is the list of recent funding rounds of Epsilico:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
2023 | 9889 | Seed | 4014 | 7749 | 8210 | 2815 |
Oct 01, 2022 | 2555279 | Grant (prize money) | 2220623 | 7069148 | 2862946 |
Access funding benchmarks and valuations. Sign up today!View details of Epsilico's funding rounds and investors
Epsilico's founders and board of directors
Founder? Claim ProfileThe founders of Epsilico are Cuong To and Christian Wirsching.
Here are the details of Epsilico's key team members:
- Cuong To: Co-Founder of Epsilico.
- Christian Wirsching: Co-Founder of Epsilico.
View details of Epsilico's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Epsilico's Competitors and alternates
Top competitors of Epsilico include BioMarin Pharmaceutical, Ultragenyx and Upstream Bio. Here is the list of Top 10 competitors of Epsilico, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | BioMarin Pharmaceutical 1997, San Rafael (United States), Public | Developer of therapeutics for the treatment of rare genetic diseases | $37.5M | 72/100 | |
2nd | Ultragenyx 2010, Novato (United States), Acquired | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 69/100 | |
3rd |  Upstream Bio 2021, Waltham (United States), Public | Developer of therapeutics for allergic and inflammatory diseases | $400M | 67/100 | |
4th |  Odyssey 2018, Cambridge (United States), Public | Developer of immunotherapeutics for immunological and cancer diseases | $717M | 66/100 | |
5th | Septerna 2020, San Bruno (United States), Public | Developer of GPCR drug discovery platform for multiple diseases | $250M | 66/100 | |
6th |  Ventyx Biosciences 2018, Encinitas (United States), Acquired | Developer of therapeutics to treat autoimmune diseases | $165M | 66/100 | |
7th |  Evommune 2020, Sacramento (United States), Public | Developer of therapeutic options for chronic inflammatory disorders | $276M | 66/100 | |
8th | CalciMedica 2006, San Diego (United States), Public | Developer of CRAC channel inhibitor drugs for inflammatory diseases | $76.7M | 64/100 | |
9th | CRISPR Therapeutics 2013, Basel (Switzerland), Public | Developer of solutions for treating human genetic diseases by using genome editing technology | $127M | 63/100 | |
10th |  AIRNA 2021, Cambridge (United States), Series B | Developer of gene therapies for rare and common diseases | $245M | 63/100 | |
177th | Generative AI technology for designing biologics | - | 36/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Epsilico's competitors? Click here to see the top ones
Epsilico's Investments and acquisitions
Epsilico has made no investments or acquisitions yet.
Reports related to Epsilico
Here is the latest report on Epsilico's sector:
Are you a Founder ?
FAQs about Epsilico
Explore our recently published companies
- Landscape Restoration - Kimberling City based, Unfunded company
- Norfolk & Norwich Landscapers - Attleborough based, Unfunded company
- Giambanco Landscaping - Norton based, 2018 founded, Unfunded company
- Aralufkin - Lufkin based, 1988 founded, Unfunded company
- Louisville Animal Exterminator - Louisville based, 2010 founded, Unfunded company
- Pine Bluff Pool Table Movers - Pine Bluff based, Unfunded company
